Related Experiment Videos

Erythema multiforme major in a 2-month-old child with human immunodeficiency virus (HIV) infection

D Salomon1, J H Saurat

  • 1Clinique de Dermatologie, Hôpital Cantonal Universitaire, Geneva, Switzerland.

Insights

A severe skin reaction, erythema multiforme, possibly triggered by phenobarbitone, occurred in an infant. The child later developed acquired immunodeficiency syndrome, suggesting congenital HIV-1 infection.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Dermatology

Background:

  • Erythema multiforme is an acute, immune-mediated mucocutaneous reaction.
  • Phenobarbitone is a known potential trigger for various adverse drug reactions.
  • Congenital Human Immunodeficiency Virus (HIV) infection presents unique challenges in infants.

Observation:

  • A severe case of erythema multiforme was observed in a 2-month-old male infant in Zimbabwe.
  • The infant's condition was potentially precipitated by phenobarbitone exposure.
  • The patient subsequently exhibited signs consistent with acquired immunodeficiency syndrome (AIDS).

Findings:

  • Serological tests indicated a congenital HIV-1 infection as the underlying cause.
  • The clinical presentation suggests a possible link between phenobarbitone and severe erythema multiforme in the context of congenital HIV-1.
  • This case highlights a rare presentation of drug-induced skin reactions in immunocompromised infants.

Implications:

  • This case underscores the importance of considering congenital HIV-1 infection in infants presenting with severe mucocutaneous reactions.
  • It emphasizes the need for careful drug monitoring in pediatric patients, especially those with underlying immune deficiencies.
  • Further research may elucidate the complex interplay between antiretroviral therapy, drug reactions, and immune status in vertically infected infants.

Related Concept Videos